Dilanubicel - Nohla Therapeutics

Drug Profile

Dilanubicel - Nohla Therapeutics

Alternative Names: Ex vivo expanded universal donor cellular therapies - Nohla Therapeutics; Ex vivo-expanded cord blood progenitor cells - Nohla Therapeutics; Haematopoetic expanded progenitor cell therapy - Nohla Therapeutics; NLA 101; Notch-mediated ex vivo expanded cord blood HSPC - Nohla Therapeutics

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; Nohla Therapeutics
  • Class Antibacterials; Antineoplastics; Radioprotectives; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies; Infections
  • Preclinical Acute radiation syndrome; Graft-versus-host disease; Neutropenia

Most Recent Events

  • 21 Mar 2018 Nohla Therapeutics signs a commercial manufacturing agreement with WuXi AppTec Advanced Therapies for manufacturing of haematopoetic stem/progenitor cell therapy
  • 24 Jan 2018 Phase-II clinical trials in Infections in USA (IV) (NCT03301597)
  • 23 Jan 2018 NLA 101 receives Orphan Drug status for Haematological malignancies in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top